Literature DB >> 28760806

p27 in FLT3-driven acute myeloid leukemia: many roads lead to ruin.

Iris Z Uras1, Florian Bellutti1, Veronika Sexl2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28760806      PMCID： PMC5541863          DOI： 10.3324/haematol.2017.171819

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  19 in total

1.  FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.

Authors:  Blanca Scheijen; Hai T Ngo; Hyun Kang; James D Griffin
Journal:  Oncogene       Date:  2004-04-22       Impact factor: 9.867

2.  p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70.

Authors:  Peng Zou; Hiroki Yoshihara; Kentaro Hosokawa; Ikue Tai; Kaori Shinmyozu; Fujiko Tsukahara; Yoshiro Maru; Keiko Nakayama; Keiichi I Nakayama; Toshio Suda
Journal:  Cell Stem Cell       Date:  2011-09-02       Impact factor: 24.633

Review 3.  Induced protein degradation: an emerging drug discovery paradigm.

Authors:  Ashton C Lai; Craig M Crews
Journal:  Nat Rev Drug Discov       Date:  2016-11-25       Impact factor: 84.694

4.  Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand.

Authors:  T S Hawley; A Z Fong; H Griesser; S D Lyman; R G Hawley
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

5.  BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.

Authors:  Anupriya Agarwal; Ryan J Mackenzie; Arnaud Besson; Sophia Jeng; Alyssa Carey; Dorian H LaTocha; Angela G Fleischman; Nicolas Duquesnes; Christopher A Eide; Kavin B Vasudevan; Marc M Loriaux; Eduardo Firpo; Jorge E Cortes; Shannon McWeeney; Thomas O'Hare; James M Roberts; Brian J Druker; Michael W Deininger
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

6.  p21Cip1 and p27Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells.

Authors:  María J Muñoz-Alonso; Juan C Acosta; Carlos Richard; M Dolores Delgado; John Sedivy; Javier León
Journal:  J Biol Chem       Date:  2005-03-03       Impact factor: 5.157

7.  Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.

Authors:  S Chu; T McDonald; R Bhatia
Journal:  Leukemia       Date:  2010-03-04       Impact factor: 11.528

Review 8.  The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.

Authors:  Isabel M Chu; Ludger Hengst; Joyce M Slingerland
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

Review 9.  The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond.

Authors:  Seth A Wander; Mark J Levis; Amir T Fathi
Journal:  Ther Adv Hematol       Date:  2014-06

10.  Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.

Authors:  Alexa S Green; Thiago T Maciel; Marie-Anne Hospital; Chae Yin; Fetta Mazed; Elizabeth C Townsend; Sylvain Pilorge; Mireille Lambert; Etienne Paubelle; Arnaud Jacquel; Florence Zylbersztejn; Justine Decroocq; Laury Poulain; Pierre Sujobert; Nathalie Jacque; Kevin Adam; Jason C C So; Olivier Kosmider; Patrick Auberger; Olivier Hermine; David M Weinstock; Catherine Lacombe; Patrick Mayeux; Gary J Vanasse; Anskar Y Leung; Ivan C Moura; Didier Bouscary; Jerome Tamburini
Journal:  Sci Adv       Date:  2015-09-18       Impact factor: 14.136
View more
  2 in total

1.  Role of alternative polyadenylation dynamics in acute myeloid leukaemia at single-cell resolution.

Authors:  Congting Ye; Qian Zhou; Yiling Hong; Qingshun Quinn Li
Journal:  RNA Biol       Date:  2019-03-13       Impact factor: 4.652

Review 2.  CDK6 Inhibition: A Novel Approach in AML Management.

Authors:  Iris Z Uras; Veronika Sexl; Karoline Kollmann
Journal:  Int J Mol Sci       Date:  2020-04-05       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.